Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.